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http://www.translational-medicine.com/content/11/1/311RESEARCH Open AccessLoss of Raf-1 kinase inhibitor protein (RKIP) is
strongly associated with high-grade tumor budding
and correlates with an aggressive phenotype in
pancreatic ductal adenocarcinoma (PDAC)
Eva Karamitopoulou1,2*, Inti Zlobec1,2, Beat Gloor3, Agathi Kondi-Pafiti4, Alessandro Lugli1,2† and Aurel Perren1,2†Abstract
Background: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of
human cancers and is known to inhibit Ras/Raf/MEK/ERK signaling. By suppressing the activation of the NFkB/SNAIL
circuit, RKIP can regulate the induction of epithelial-mesenchymal transition (EMT). The aim of this study was to
evaluate RKIP expression and to determine its association with clinicopathological features, including EMT in form
of tumor budding in pancreatic ductal adenocarcinoma (PDAC).
Methods: Staining for RKIP was performed on a multipunch Tissue Microarray (TMA) of 114 well-characterized
PDACs with clinico-pathological, follow-up and adjuvant therapy information. RKIP-expression was assessed
separately in the main tumor body and in the tumor buds. Another 3 TMAs containing normal pancreatic tissue,
precursor lesions (Pancreatic Intraepithelial Neoplasia, PanINs) and matched lymph node metastases were stained in
parallel. Cut-off values were calculated by receiver operating characteristic (ROC) curve analysis.
Results: We found a significant progressive loss of RKIP expression between normal pancreatic ductal epithelia
(average: 74%), precursor lesions (PanINs; average: 37%), PDAC (average 20%) and lymph node metastases
(average 8%, p < 0.0001). RKIP expression was significantly lower in tumor buds (average: 6%) compared to the
main tumor body (average 20%; p < 0.005). RKIP loss in the tumor body was marginally associated with advanced
T-stage (p = 0.0599) as well as high-grade peritumoral (p = 0.0048) and intratumoral budding (p = 0.0373). RKIP loss
in the buds showed a clear association with advanced T stage (p = 0.0089).
Conclusions: The progressive loss of RKIP seems to play a major role in the neoplastic transformation of pancreas,
correlates with aggressive features in PDAC and is associated with the presence of EMT in form of tumor budding.
Keywords: RKIP, Pancreatic cancer, Epithelial-mesenchymal transition, Tumor budsBackground
RAF kinase inhibitor protein (RKIP; also known as PEBP,
for phosphatidylethanolamine-binding protein) is consid-
ered a metastasis suppressor protein, acting as an endogen-
ous inhibitor of the Raf–mitogen-activated protein (MAP)
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distribution, and reproduction in any mediumpathway by inhibiting the phosphorylation and activation of
MEK by Raf-1 [1,2]. It has additionally been shown that
RKIP suppresses the activation of the NFkB/SNAIL circuit
[3-6]. This pathway plays an important role in the induction
of epithelial mesenchymal transition (EMT) of cancer cells
as one of the initial steps for metastatic spread [3-6].
A reduced RKIP expression has been shown to be as-
sociated with tumor progression and unfavourable prog-
nosis in a variety of human malignant tumors [7-9]. In
recent studies performed by our group on colorectal
cancer (CRC), we could demonstrate that RKIP status,
when combined with N stage and vascular invasion canCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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static disease [10]. In a TMA-based profiling of multi-
marker phenotypes of CRC, we identified RKIP as a
predictor of high grade tumor budding with a differen-
tial expression between tumor center and tumor front
[11,12]. Moreover, in a geographic analysis of RKIP on
whole tissue sections of CRC, we demonstrated that
loss of RKIP expression in the tumor center was an
independent prognostic factor and could predict the
chemotherapy response [13].
Pancreatic ductal adenocarcinoma (PDAC) is a com-
mon cause of cancer death and has a dismal prognosis
[14]. Most patients have advanced stage disease at
presentation with a median survival of less than 1 year
[15]. Therapeutic options are limited with surgical re-
section being the only potentially curative treatment.
Classical histopathologic findings as tumor size, blood
vessel or lymphatic invasion and presence of lymph
node metastases constitute essential prognostic factors
in pancreatic cancer with tumor stage being the most
important of all [16]. The lethal nature of PDAC has
been attributed to the propensity of PDAC cells to rap-
idly disseminate to the lymphatic system and distant
organs [17]. Within this context and considering the
fact that the management of PDAC remains subopti-
mal and that adjuvant therapy has resulted to limited
progress, there is a need for additional reliable and re-
producible prognostic markers that would enable better
patient stratification and would provide a guide towards
an individualized therapy.
Tumor budding reflects a type of diffusely infiltrative
growth frequently observed in gastrointestinal carcinomas
and it is defined as the presence of detached, isolated
single cells or small cell clusters (up to 5 cells) scat-
tered in the stroma at the invasive tumor front [18-25]
and has been suggested to actually reflect the process
of EMT [26,27]. In a previous study from our group we
could show that tumor budding occurs frequently in
pancreatic cancer and may be used as a parameter of
tumor aggressiveness and as an indicator of unfavourable
outcome, even within this group of patients with generally
poor prognosis [28].
Due to our previous findings on colorectal cancer, we
hypothesized that loss of RKIP may be associated with
the frequent occurrence of tumor budding in pancreatic
cancer and may play a role in pancreatic carcinogenesis.
We therefore undertook the analysis of RKIP expression
on a multi-punch TMA from a well-characterized cohort
of 120 pancreatic ductal adenocarcinomas (PDACs),
their precursor lesions (PanINs) and matched lymph
node metastases. RKIP expression was correlated with
clinicopathological data and especially with the presence
of tumor budding. The REMARK guidelines were used
as a basis for this biomarker study [29].Material and methods
Patients and specimen characteristics
120 non-consecutive PDAC patients surgically treated
between 2000 and 2010 were randomly selected. Paraffin-
embedded tissue blocks of primary tumors were retrieved
from the Department of Pathology, Aretaieion University
Hospital, University of Athens Medical School, Greece.
All histomorphological data were reviewed from the
corresponding hematoxylin and eosin (H&E) stained
slides, while clinical data were obtained from chart reports.
Clinicopathological information for all patients included
age, gender, tumor diameter, number of positive lymph
nodes and total number of lymph nodes harvested, TNM
stage (7th Edition), perineural, as well as blood vessel and
lymphatic invasion and resection margin status (R-status).
Information on post-operative therapy was available for
all patients. The use of this material was approved by
the local ethics committees of the University of Athens
and University of Bern.
Assay methods
a. Construction of tissue microarray (TMA)
For each patient, the hematoxylin and eosin slides of the
primary tumor from the corresponding whole tissue sections
were evaluated and representative areas of the tissue were
marked using a felt-tip pen for easy detection. To exclude
bias because of possible tumor heterogeneity, each patient
had 4 tumor punches (2 tumor center + 2 tumor front)
taken from formalin-fixed, paraffin-embedded blocks
using a tissue cylinder with a diameter of 0.6 mm that
were subsequently transferred into 1 recipient paraffin block
(3 × 2.5 cm) using a homemade semiautomated tissue
arrayer. Tissues were obtained from the tumor center and
the invasive tumor front so that each patient had at least
4 tumor punches included on this array (total of 480
punches). Three additional one-punch TMAs were con-
structed including normal pancreatic tissue (147 punches),
precursor lesions (PanINs; 123 punches) and matched
lymph node metastases (94 punches).
b. Immunohistochemistry
TMA blocks were cut at 4 μm and immunostained
for pan-cytokeratin AE1/AE3 (Monosan; 1:100), that
served to highlight areas of tumor budding and RKIP
(Merck Millipore, Billerica, MA; 1:100). Sections were
de-waxed and re-hydrated in dH2O. RKIP staining was
performed using a Bond Max Autostainer from Leica
Microsystem (Wetzlar, Germany) with antigen retrieval
performed in citrate buffer at 100 for 20 min. Normal
pancreatic tissue and nerve tissue served as an internal
positive control. Negative control was obtained by
omitting the primary antibody. Whole tissue sections
of 5 randomly selected cases were stained in parallel as
validation of the TMA results.
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Tumor budding was defined as detached single cells
or clusters of < 5 cells. Cases were evaluated for tumor
budding using a 10-in-10 approach [30]. Briefly, whole
tissue sections of each case underwent immunohisto-
chemistry for AE1/AE3 (pan-cytokeratin) staining.
The 10 densest hot-spots of tumor budding were
evaluated at high-magnification (40x, 0.55 mm2) and
counted. The average number of buds per case was
obtained. Although tumor budding is described to occur
mostly at the invasive front of cancers (peritumoral
budding), in our PDAC series we frequently observed
the presence of buds within the main tumor body as
well (intratumoral budding). Using a receiver operat-
ing characteristic (ROC) curve approach, a cut-off
score of 10 buds on average was identified as most
discriminatory for survival. Cases with an average of >10
buds were classified as “high-grade” budders; those
with ≤10 buds were assigned as “low-grade” budders
[30] (Figure 1).Figure 1 AE1/AE3 (Pancytokeratin) and H&E staining in PDAC to dem
(Pancytokeratin): Low-grade tumor budding; C (H&E) and D (Pancytokd. Assessment of RKIP staining
Immunohistochemistry was evaluated by estimating visually
the percentage of positive cells per tissue microarray punch
in 5% intervals (0%, 5%, …, 100%). In the case of multiple
tumor punches per localization, the average protein
expression was calculated across all punches from the
same localization. The end result was that each patient
had a final protein expression score for the main tumor
body, the tumor buds, the matched lymph node metastases,
the precursor lesions (PanINs) and the normal pancreatic
tissue (ductal epithelia). Evaluation was performed blinded
to clinical endpoints.
e. Statistical analysis
In order to determine a valid cut-off score for RKIP
expression (low/high), receiver operating characteristic
(ROC) curve analysis was performed, using the end-
point of tumor budding. A threshold value of 10% was
identified. Association of RKIP expression with categorical
clinicopathological features was performed using theonstrate the presence of tumor budding (x200): A (H&E) and B
eratin): High-grade tumor budding.
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Exact tests; for continuous variables such as age and tumor
size, the non-parametric Wilcoxon’s Rank Sum test was
used. For matched analyses, the Wilcoxon’s Signed Rank
test for pairs and the Cochran-Mantel-Haenszel test for
three of more groups were used. Logistic regression analysis
was used to determine the odds ratio (OR) and 95%CI for
loss of RKIP expression with certain clinicopathological
features. Missing data were few and were assumed to be
missing at random. No imputation for missing values was
performed. Univariate survival time analysis was performed
using the log-rank test and differences plotted using
Kaplan-Meier curves. P-values <0.05 were considered
statistically significant. Correction for multiple hypothesis
testing was not carried out [31]. Analyses were carried out
using SAS (V9.2; The SAS Institute, Cary, NC).Table 1 Association of RKIP expression in main tumor with cl
Feature Total N (%)
Sex (n = 113) Female 52 (46.0)
Male 61 (54.0)
Age at diagnosis (yrs) (n = 112) Median (min, max) 65 (35–84)
Tumor size (cm) (n = 109) Median (min, max) 3.0 (1.2-10)
pT classification (n = 112) pT1-2 10 (8.9)
pT3-4 102 (91.1)
Tumor grade (n = 114) G1-2 16 (14.0)
G3 98 (86.0)
pN classification (n = 112) pN0 20 (17.9)
pN1-2 92 (82.1)
pM classification (n = 112) pM0 103 (92.0)
pM1 9 (8.0)
Pn classification (n = 110) Pn0 1 (0.9)
Pn1 109 (99.1)
Lymphatic invasion (n = 112) Negative 21 (18.8)
Positive 91 (81.3)
Venous invasion (n = 112) Negative 88 (78.6)
Positive 24 (21.4)
R classification (n = 111) R0 78 (70.3)
R1 33 (29.7)
Adjuvant chemo (n = 105) Untreated 3 (2.9)
Treated 102 (97.1)
Tumor budding 10-in-10 Low-grade 33 (30.8)
(n = 107) High-grade 77 (69.2)
Intratumoral budding Negative/Low 48 (42.9)
(n = 112) Medium/High 64 (57.1)
Cutoff 10% (ROC cutoff value).
*Odds ratio estimate for high-grade tumor budding predicted by loss of RKIP is OR
** Odds ratio estimate of medium/high grade budding predicted by loss of RKIP isResults
Patient characteristics and RKIP expression (Table 1)
One hundred and twenty patients with PDAC were
included in this study. RKIP expression could be success-
fully evaluated in 114 and included 33 cases (29%) with
low-expression and 81 cases (71.1%) with high-expression.
Median overall survival (OS) for the cohort of 114 patients
was 11 months (95%CI: 10–13), while the median disease-
free interval (DFI) was 5.0 months (95%CI: 4–6). Patient
characteristics are outlined in Table 1.
RKIP expression normal-PanIN-carcinoma-metastasis sequence
A panel of representative examples of RKIP expression
can be seen in Figure 2, including examples of normal
pancreatic tissue, PanINs and cancer tissue with and
without budding.inicopathological features (n = 114)
Frequency N (%) P-value
Low (n = 33; 29.0%) High (n = 81; 71.1%)
17 (53.1) 35 (43.2) 0.4573
15 (46.9) 46 (56.8)
65 (42–83) 65 (35–84) 0.8265
3.0 (1.3-6.5) 3.0 (1.2-10) 0.5498
0 (0.0) 10 (12.5) 0.0599°
32 (100.0) 70 (87.5)
2 (6.1) 14 (17.3) 0.205
31 (93.9) 67 (82.7)
5 (15.6) 15 (18.8) 0.9068
27 (84.4) 65 (81.3)
28 (87.5) 75 (93.8) 0.4749
4 (12.5) 5 (6.3)
0 (0.0) 1 (1.3) 1.0
32 (100.0) 77 (98.7)
4 (12.5) 17 (21.3) 0.4215
28 (87.5) 63 (78.8)
24 (75.0) 64 (80.0) 0.7431
8 (25.0) 16 (20.0)
21 (65.6) 57 (72.2) 0.6511
11 (34.4) 22 (27.9)
0 (0.0) 3 (4.1) 0.6204
31 (100.0) 71 (96.0)
3 (10.3) 30 (38.5) 0.0048 *
26 (89.7) 48 (61.5)
9 (27.3) 39 (49.4) 0.0373 **
24 (72.7) 40 (50.6)
(95%CI): 5.42 (1.51-19.5).
OR (95%CI): 2.6 (1.07-6.29).
Figure 2 Representative examples of RKIP staining: A: normal pancreatic tissue with strong RKIP expression (x200); B: An example of
PanIN (upper right) with reduced RKIP expression compared to the normal tissue (left side of the image; x200); C: An example of
PDAC with low-grade budding and retained RKIP expression (x200); D: PDAC with loss of RKIP expression. A peripheral nerve (lower left)
with strong RKIP staining (x200); E: PDAC with many tumor buds and loss of RKIP expression (x200); F: an example of PDAC with loss of RKIP
expression in the buds (arrows) compared to the main tumor body (x400); G: PDAC with high-grade tumor budding and loss of RKIP expression
(x200); H: Lymph node metastasis of PDAC with loss of RKIP expression (x200).
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nificant and striking progressive loss of RKIP expression
was found from the normal pancreatic tissue including nor-
mal ductal epithelia (73.8%) to PanIN (36.7%), then to car-
cinoma (20%) and finally to lymph node metastases (8.3%)
(p < 0.0001). Interestingly, within tumor budding cells of
the primary carcinomas, RKIP expression was nearly absent
(average expression 6%) (Figure 3). Using a matched pairs
analysis (signed rank test) to test the difference between
RKIP expression in the tumor and corresponding tumor
buds, a statistical significant loss of expression (p < 0.0001)
was observed. The parallel stained whole tissue sections
revealed the same findings (Figure 4).
RKIP expression and clinicopathological data
Table 1 highlights the associations between RKIP expres-
sion and clinicopathological features in PDAC. Using
Fisher’s Exact test, a statistically significant association
between high-grade tumor budding and loss of RKIP
expression was observed (p = 0.0048). Similar results
were found for intratumoral budding (p = 0.0373). In
order to underline the relationship between high-grade
tumor budding and loss of RKIP, logistic regression
analysis was performed. OR (95%CI) for high-grade
budding was 5.42 (1.51-19.5), indicating that the odds
of such a phenotype were more than 5x more likely in
patients with RKIP loss in comparison to those withhighly expressing tumors. The sensitivity, specificity and
accuracy for this finding were 0.909, 0.35, and 0.63, re-
spectively. Similarly, the odds of intratumoral budding
were 2.6 (95%CI: 1.07-6.29) times greater in patients with
loss of RKIP as compared to patients with high expression
of the protein. Sensitivity, specificity and accuracy were
0.812, 0.375, and 0.594, respectively. There was no associ-
ation with overall survival (p = 0.412) or with disease-free
interval (p = 0.335) (Figure 5).
Table 2 shows the association of RKIP expression within
tumor budding cells themselves and clinicopathological
features. Loss of RKIP expression within tumors buds
themselves was significantly more frequent in patients
with pT3-4 (p = 0.0089) carcinomas. There was no asso-
ciation between overall survival (p = 0.6683) or disease-
free interval (p = 0.8572).
Discussion
This study is presenting a novel approach concerning
the analysis of RKIP expression in pancreatic cancer,
considering not only the expression pattern in the main
tumor body but also in the tumor buds, in association
with tumor and patient characteristics, in a well charac-
terized cohort of 114 PDAC patients with known follow-
up and adjuvant therapy information. The present study
expands our understanding on the role of RKIP in pan-
creatic cancer on several aspects. First of all, we found a
Figure 3 Distribution of average RKIP expression according to Histology.
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normal pancreatic ductal epithelia (average: 73.76%),
precursor lesions (PanINs; average: 36.71%), pancreatic
cancer (average 20%) and matched lymph node metasta-
ses (average 8.3%; p < 0.0001). This implies that progres-
sive RKIP loss may play a key role in the pancreatic
neoplastic transformation and that it is taking place even
before invasion occurs. Similar findings were observed in
a previous study concerning esophageal Barrett mucosa,
where a down-regulation of RKIP was found in high-grade
dysplasia compared with non-dysplastic lesions [32].
Our findings are partially in keeping with previous
studies on RKIP expression on pancreatic cancer, which
have also demonstrated a significant RKIP loss in cancer
tissues compared with normal pancreatic tissue and an as-
sociation of RKIP loss with presence of nodal and/or distant
metastases as well as reduced patient survival [33,34]. In
our cohort, however, no significant correlation of RKIP loss
with nodal (pN stage) or distant metastases (pM stage)
was found. This could be due to differences in the patient
cohorts, the different immunohistochemical methods and
assessment protocols as well as different cut-offs used.
RKIP has been found to play a major role in the regu-
lation of EMT by intervening in Raf-1/MEK/ERK and
NF-kB mediated signaling [3-6]. NF-kb activation and
subsequent activation of its downstream transcriptional
target SNAIL induces EMT through down-regulation
of E-cadherin and negatively regulates RKIP in cancer
cells [35]. Moreover, RKIP loss enhances cellular motility
by inducing the expression/stabilization of β-catenin,
vimentin, MET and PAK1 [36] and augments oxidative
stress–mediated activation of the p38 mitogen activated
protein kinase, which, in turn, inactivates Glycogen
synthase kinase-3b (GSK3b) by phosphorylating it at
the inhibitory T390 residue. This pathway de-repressesGSK3b inhibition of oncogenic substrates causing
stabilization of cyclin D, which induces cell-cycle progres-
sion and β-catenin, SNAIL, and SLUG, which promote
EMT [37]. In keeping with this, our study demonstrates a
strong correlation of the RKIP loss with morphological
hallmarks of EMT, like high-grade tumor budding at the
invasive tumor front (p = 0.0048). The association of RKIP
loss with high-grade budding remained strong when
analyzing intratumoral budding, occuring within the
main tumor body (p = 0.0373).
Further, we identified a variation of RKIP protein expres-
sion between the main tumor body and the tumor buds.
RKIP expression was found to be significantly and consist-
ently lower in the tumor buds (average 6%) compared to
the main tumor body (average 20%; p < 0.005). Moreover,
after using a matched pairs analysis a statistically significant
loss of RKIP expression (p < 0.0001) was observed between
the tumor and corresponding tumor buds. Our results
suggest that this variation in the localisation of RKIP loss
within the cancer tissue is relevant for the association with
specific aggressive phenotypic features. RKIP loss in the
main tumor body was marginally associated with higher
T-stage (0.0599) as well as with the presence of peritumoral
(0.0048) and intratumoral budding (p = 0.0373), while RKIP
loss in the tumor buds exhibited a significant association
with increased T stage (p = 0.0089). This finding underlines
the predictive role of RKIP loss in the main tumor
body concerning the presence of high-grade budding
throughout the tumor. Additional RKIP loss in the tumor
buds themselves seems to be involved in the propagation
of the neoplastic process and to lead to increased aggres-
siveness of the neoplasm.
RKIP, by inhibiting the Raf-MEK-ERK, NFκB, GRK and
activating the GSK3β signaling pathways is implicated in
the sensitization of cells to therapeutic drugs. When its
Figure 4 Examples of whole tissue sections of PDAC cases immunostained for RKIP (x200). A: positive immunostaining for RKIP in PDAC.
Note the absence of tumor buds. B: Normal pancreatic tissue (upper left) with retained RKIP-positivity. Reduced RKIPexpression in the adjacent
PDAC. C: Reduced RKIP-expression in PDAC and absent RKIPexpression in the tumor buds (arrows).
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resistance to cancer therapy [38]. However, unlike other
tumor types, like colorectal cancer, we could not identify
any association between loss of RKIP and treatment re-
sponse in our pancreatic cancer cohort. Because of the small
number of untreated patients in this study (only 3 patients)
no statistical comparison between treated and untreated
patients could be performed.Our present results should be understood in the context
of the study limitations. Although TMAs provide an effi-
cient and cost-effective tool for testing a comprehensive
panel of potential biomarkers on a large number of tumor
specimens, the TMA technique could raise concerns
related to the sampling of large, heterogeneous tumors.
The effect of tumor heterogeneity was minimized by
sampling at least two punches from the center and two
Table 2 Association of RKIP expression in tumor buds with clinicopathological features (n = 98)
Feature Frequency N (%) P-value
Low (n = 68; 69.4) High (n = 30; 30.6)
Sex (n = 97) Male 42 (62.7) 12 (40.0) 0.0476
Female 25 (37.3) 18 (60.0)
Age at diagnosis (yrs) Median (min, max) 65 (42–83) 61 (35–84) 0.914
Tumor size (cm) Median (min, max) 3 (1.2-6.5) 3.3 (1.2-10) 0.6526
pT classification (n = 97) pT1-2 3 (4.5) 7 (23.3) 0.0089
pT3-4 64 (95.5) 23 (76.7)
Tumor grade (n = 98) G1-2 8 (11.8) 3 (10.0) 1.0
G3 60 (88.2) 27 (90.0)
pN classification (n = 97) pN0 12 (17.9) 5 (16.7) 1.0
pN1-2 55 (82.1) 25 (83.3)
pM classification (n = 97) pM0 62 (92.5) 27 (90.0) 0.6996
pM1 5 (7.5) 3 (10.0)
Pn classification (n = 96) Pn0 0 (0.0) 1 (3.5) 0.3021
Pn1 67 (100.0) 28 (96.6)
Lymphatic invasion (n = 97) Negative 13 (19.4) 6 (200.) 1.0
Positive 54 (80.6) 24 (80.0)
Venous invasion (n = 97) Negative 53 (79.1) 22 (73.3) 0.6025
Positive 14 (20.9) 8 (26.7)
R classification (n = 97) R0 45 (67.2) 22 (73.3) 0.6382
R1 22 (32.8) 8 (26.7)
Adjuvant chemo (n = 89) Untreated 1 (1.6) 2 (7.4) 0.2174
Treated 61 (98.4) 25 (92.6)
Tumor budding 10-in-10 Low-grade 16 (26.2) 10 (33.3) 0.6221
(n = 91) High-grade 45 (73.8) 20 (66.7)
Intratumoral budding Negative/Low 26 (38.2) 12 (41.4) 0.8224
(n = 97) Medium/High 42 (61.8) 17 (58.6)
°Fisher’s Exact test
Cutoff 10%.
Figure 5 Kaplan-Meier curves illustrating absence of survival time differences for patients with low or high RKIP expression.
A) Overall survival; B) Disease-free interval.
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expression across the total number of samples. Our study
may further be limited by the relatively small number of
PDAC patients and the fact that all cases come from a
single center. Nonetheless, our study benefits from
complete clinicopathological data with information on
adjuvant therapy and follow-up and the adherence to
the REMARK guidelines which are essential for proposing
prognostic biomarkers.
In conclusion, our findings suggest that progressive
loss of RKIP may play a key role in the neoplastic
transformation of pancreas and correlates with aggres-
sive features of PDAC. Moreover, RKIP loss seems to
be strongly associated with EMT in pancreatic cancer,
as reflected by the presence of high-grade tumor budding.
Further characterization of the budding cells is needed in
order to identify a “budding-promoting profile” and to
underline the similarities between budding cells and EMT
process in pancreatic cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EK has made substantial contributions to conception and design, to
acquisition and interpretation of data and has drafted the manuscript. IZ
performed the statistical analysis and has been involved in revising the
manuscript critically for important intellectual content. BG has been involved
in revising the manuscript critically for important intellectual content. AKP
has made substantial contributions to acquisition of data and has been
involved in revising the manuscript critically for important intellectual
content, AL participated in the design and coordination of the study, has
been involved in revising the manuscript critically for important intellectual
content and has given the final approval of the version to be published. AP
participated in the design and coordination of the study, has been involved
in revising the manuscript critically for important intellectual content and has
given the final approval of the version to be published. All authors read and
approved the final manuscript.
Author details
1Clinical Pathology Division, University of Bern, Murtenstrasse 31, Bern,
Switzerland. 2Institute of Pathology, Translational Research Unit, University of
Bern, Murtenstrasse 31, Bern, Switzerland. 3Department of Visceral Surgery,
Insel University Hospital, Bern, Switzerland. 4Department of Pathology,
Aretaieion University Hospital, University of Athens, Athens, Greece.
Received: 3 July 2013 Accepted: 12 November 2013
Published: 14 December 2013
References
1. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W:
Mechanism of suppression of the Raf/MEK/extracellular signal-regulated
kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000,
20:3079–3085.
2. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD,
Rose DW, Mischak H, Sedivy JM, Kolch W: Suppression of Raf-1 kinase activity
and MAP kinase signalling by RKIP. Nature 1999, 401(6749):173–177.
3. Wu K, Bonavida B: The activated NF-kappaB-Snail-RKIP circuitry in cancer
regulates both the metastatic cascade and resistance to apoptosis by
cytotoxic drugs. Crit Rev Immunol 2009, 29:241–254.
4. Tang H, Park S, Sun SC, Trumbly R, Ren G, Tsung E, Yeung KC: RKIP inhibits
NF-kappaB in cancer cells by regulating upstream signaling components
of the IkappaB ninase complex. FEBS Lett 2010, 584:662–668.
5. Al-Mulla F, Bitar MS, Taqi Z, Yeung KC: RKIP: much more than Raf kinase
inhibitory protein. J Cell Physiol 2013, 228:1688–1702.6. Al-Mulla F: RKIP and cellular motility. J Cell Physiol 2012, 227:2969–2970.
7. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET: Effects of raf
kinase inhibitor protein expression on suppression of prostate cancer
metastasis. J Natl Cancer Inst 2003, 95:878–889.
8. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK: Reduction in raf
kinase inhibitor protein expression is associated with increased
Ras-extracellular signal-regulated kinase signaling in melanoma cell lines.
Cancer Res 2004, 64:5186–5192.
9. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch
W: Reduction of Raf-1 kinase inhibitor protein expression correlates with
breast cancer metastasis. Clin Cancer Res 2005, 11:7392–7397.
10. Zlobec I, Baker K, Minoo P, Jass JR, Terracciano L, Lugli A: Node-negative
colorectal cancer at high risk of distant metastasis identified by
combined analysis of lymph node status, vascular invasion and Raf-1
kinase inhibitor protein expression. Clin Cancer Res 2008, 14:143–148.
11. Karamitopoulou E, Lugli A, Patsouris E, Panayiotides I, Karakitsos P, Rallis G,
Peros G, Terracciano L, Zlobec I: Systematic assessment of protein
phenotypes characterizing high-grade tumour budding in mismatch
repair-proficient colorectal cancer. Histopathology 2010, 57:233–243.
12. Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris E, Peros G, Rallis G,
Terracciano L, Lugli A: Systematic analysis of proteins from different
signalling pathways in the tumor centre and the invasive front of
colorectal cancer. Hum Pathol 2011, 42:1888–1896.
13. Koelzer V, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A:
Geographic analysis of RKIP expression and its clinical relevance in
colorectal cancer. Br J Cancer 2013, 108:2088–2096.
14. Hidalgo M: Pancreatic cancer. NEJM 2010, 362:1605–1617.
15. Stathis A, Moore MJ: Advanced pancreatic carcinoma: current treatment
and future challenges. Nat Rev Clin Oncol 2010, 7:163–172.
16. Fernandez-del-Castillo C, Jimenez RE, Steer ML: Surgery in the
treatment of exocrine pancreas and prognosis. In Edited by Tanabe
KK. www.uptodate.com.
17. Li Y, Kong D, Ahmad A, Bao B, Sarkar FH: Pancreatic cancer stem cells:
emerging target for designing novel therapy. Cancer Lett 2012. dx.doi.org/
10.1016/ j.canlet.2012.03.018.
18. Prall F: Tumour budding in colorectal carcinoma. Histopathology 2007,
50:151–162.
19. Brown M, Sillah K, Griffiths EA, Swindell R, West CM, Page RD, Welch IM,
Pritchard SA: Tumour budding and a low host inflammatory response are
associated with a poor prognosis in oesophageal and gastro-oesophageal
junction cancers. Histopathology 2010, 56:893–899.
20. Koike M, Kodera Y, Itoh Y, Nakayama G, Fujiwara M, Hamajima N, Nakao A:
Multivariate analysis of the pathologic features of esophageal squamous
cell cancer: tumor budding is a significant independent prognostic
factor. Annals Surg Oncol 2008, 15:1977–1982.
21. Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y,
Nishida T, Mano M, Mori M, Doki Y: Tumor budding in tumor invasive
front predicts prognosis and survival of patients with esophageal
squamous cell carcinomas receiving neoadjuvant chemotherapy.
Cancer 2009, 115:3324–3334.
22. Roh MS, Lee JI, Choi PJ: Tumor budding as a useful prognostic marker in
esophageal squamous cell carcinoma. Dis Esophagus 2004, 17:333–337.
23. Gabbert H, Wagner R, Moll R, Gerharz CD: Tumor dedifferentiation: an
important step in tumor invasion. Clin Exp Metastasis 1985, 3:257–279.
24. Gabbert HE, Meier S, Gerharz CD, Hommel G: Tumor-cell dissociation at
the invasion front: a new prognostic parameter in gastric cancer
patients. Int J Cancer 1992, 50:202–207.
25. Ohike N, Coban I, Kim GE, Basturk O, Tajiri T, Krasinskas A, Bandyopadhyay S,
Morohoshi T, Shimada Y, Kooby DA, Staley CA, Goodman M, Adsay NV:
Tumor budding as a strong prognostic indicator in invasive ampullary
adenocarcinomas. Am J Surg Pathol 2010, 34:1417–1424.
26. Brabletz T, Spaderna S, Kolb J, Hlubek F, Faller G, Bruns CJ, Jung A,
Nentwich J, Duluc I, Domon-Dell C, Kirchner T, Freund JN: Down-regulation
of the homeodomain factor Cdx2 in colorectal cancer by collagen type I:
an active role for the tumor environment in malignant tumor progression.
Cancer Res 2004, 64:6973–6977.
27. Kalluri R: EMT: when epithelial cells decide to become mesenchymal-like
cells. J Clin Invest 2009, 119:1417–1419.
28. Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Patsouris E, Gennatas K,
Lykoudis P, Gloor B, Lugli A: Tumor budding is a strong and independent
prognostic factor in pancreatic cancer. Eur J Cancer 2013, 49:1032–1039.
Karamitopoulou et al. Journal of Translational Medicine 2013, 11:311 Page 10 of 10
http://www.translational-medicine.com/content/11/1/31129. McShane L, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: For the
statistics subcommittee of the NCI-EORTC working group on cancer
diagnostics. REporting recommendations for tumor MARKer prognostic
studies (REMARK). Eur J Cancer 2005, 41:1690–1696.
30. Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas
K, Lugli A: Proposal for a 10-high-power-fields scoring method for the
assessment of tumor budding in colorectal cancer. Mod Pathol 2013,
26:295–301.
31. Perneger TV: Adjusting for multiple testing in studies is less important
than other concerns. BMJ 1999, 318(7193):1288.
32. Birner P, Jesch B, Schultheis A, Schoppmann SF: RAF-kinase inhibitor
protein (RKIP) downregulation in esophageal cancer and its metastases.
Clin Exp Metastasis 2012, 29:551–559.
33. Kim HS, Kim GY, Lim SJ, Kim YW: Loss of Raf-1 kinase inhibitory protein in
pancreatic ductal adenocarcinoma. Pathology 2010, 42:655–660.
34. Song SP, Zhang SB, Li ZH, Zhou YS, Li B, Bian ZW, Liao QD, Zhang YD:
Reduced expression of Raf kinase inhibitor protein correlates with poor
prognosis in pancreatic cancer. Clin Transl Oncol 2012, 14:848–852.
35. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP: Stabilization of snail
by NF-kappaB is required for inflammation-induced cell migration and
invasion. Cancer Cell 2009, 15:416–428.
36. Al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W: RAF kinase inhibitory protein
(RKIP) modulates cell cycle kinetics and motility. Mol Biosyst 2011, 7(3):928–941.
37. Al-Mulla F, Bitar MS, Al-Maghrebi M, Behbehani AI, Al-Ali W, Rath O, Doyle B,
Tan KY, Pitt A, Kolch W: Raf kinase inhibitor protein RKIP enhances signaling
by glycogen synthase kinase-3b. Cancer Res 2011, 71(4):1334–1343.
38. Al-Mulla F, Bitar MS, Feng J, Park S, Yeung KC: A new model for raf kinase
inhibitory protein induced chemotherapeutic resistance. PLoS One 2012,
7(1):e29532. doi: 10.1371/journal.pone.0029532. Epub 2012 Jan 18.
doi:10.1186/1479-5876-11-311
Cite this article as: Karamitopoulou et al.: Loss of Raf-1 kinase inhibitor
protein (RKIP) is strongly associated with high-grade tumor budding and
correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma
(PDAC). Journal of Translational Medicine 2013 11:311.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
